Original Article
Prophylaxis of Macular Edema with
Peroperative Intravitreal Bevacizumab in Patients with Diabetic Retinopathy
Undergoing Phacoemulsification
Sidra Jabeen, Rizwan Khan,
Ali Raza
Pak J Ophthalmol 2019, Vol. 35, No. 1
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See end of article for authors affiliations …..……………………….. Correspondence to: Dr. Sidra Jabeen FCPS, Ophthalmology
Department, Holy Family Hospital, Rawalpindi Email: sidrajabeen16@gmail.com |
Purpose: To determine frequency of
post-operative macular edema in patients with diabetic retinopathy receiving
peroperative Intravitreal bevacizumab, as compared to controls after
phacoemulsification cataract surgery. Study Design: Randomized control trial. Place and Duration of Study:
Ophthalmology department holy family hospital Rawalpindi from July, 2016 to
January, 2017. Materials and Methods: 60
patients who reported at the health care facility with diabetic retinopathy
were included in the study. Out of these 30 were kept as control and 30 as
cases. Data was collected and entered into SPSS version 19.0. Numerical
variables were accounted for as mean and standard deviation whereas
qualitative variables were accounted for as frequency and percentages. To
compare the occurrence of macular edema at completion of 6 weeks in both
study groups, Pearson’s chi-square test at 5% level of significance was
applied. A p- value of 0.05 was considered as statistically significant. To
control effect modifier by gender, and age, stratified analysis was also
executed. Results: The participants of the study
had mean age of 61.97 ± 5.7 years. Out of the 60 patients 33 (55%) were
female. Analysis of both groups showed that macular edema was found in 4
(13.33%) patients in control group and 17 (56.67%) patients in group B. Most
significant macular edema was seen in 11 patients in age group of 61-70
years. Gender wise stratification showed that 9 (56.5%) female patients reported
with macular edema. Conclusion: Peroperative intravitreal
bevacizumab is effective in prophylaxis of macular edema in patients with
mild to moderate NPDR, as compared to controls, Keywords: NPDR, Intravitreal
bevacizumab, Diabetic Retinopathy, Macular edema, Phacemulsification surgery. |
Macular edema (ME) is defined as abnormal
thickening of the macula due to excessive accumulation of fluid in extracellular
spaces of central retina.1 It is a leading cause of irreversible
vision loss, in the ocular conditions such as diabetic retinopathy, venous
occlusion, uveitis, after cataract surgery, ocular inflammations, and branch
retinal vein occlusion2. Diabetic macular edema (DME) is a
noteworthy reason for loss of central vision in diabetic patients. Post
cataract surgery visual outcomes can be negatively affected by diabetic
maculopathy3.
It has been proposed that among diabetic
patients undergoing uncomplicated cataract surgery 22% develop an increment of >
30% in central macular thickness as quantified by optical coherence tomography
(OCT)3. Another study showed an increment of maximum macular
thickness of at least 11% was found in 25.7% of the diabetic retinopathy (DR)
eyes undergoing cataract surgery, but no such increase occurred in the
non-diabetic retinopathy control eyes4.
Increase in vascular permeability because
of diabetes mellitus brings about extravasation of plasma constituents into the
retina prompting DME; Vascular endothelial growth factor (VEGF) is documented
to be basic underlying pathogenic factor for development and progression of
macular edema auxiliary to Diabetes5. VEGF is produced by normal
retinal pigment epithelial cells under hypoxic stress. Eyes with substantial
spillage from retinal microvasculature leading to thickening of macula have
altogether higher VEGF levels when contrasted with eyes with less spillage. Subsequently,
anti VEGF agents are reflected as an adjunctive treatment for DME5.
Anti VEGF therapy can lead to decreased leakage from blood vessels6
Bevacizumab is a full-length monoclonal
humanized antibody that binds and blocks all isoforms of the VEGF-A family.
Food and drug administration (FDA) has approved its use in the management of
colorectal carcinoma5. Currently its use in ophthalmology is
off-label. Numerous studies have suggested the prophylactic use of either anti
VEGF or steroids as an intravitreal injection after phacoemulsification in
patients with diabetic exudative maculopathy to improve the final surgical
outcomes in terms of visual acuity and to keep the increase in thickness of
macula3.
The objective of the study was to determine
frequency of macular edema in patients of mild to moderate non-proliferative
diabetic retinopathy (NPDR) receiving peroperative intravitreal bevacizumab, as
compared to controls, at completion of 1month after phacoemulsification
cataract surgery.
To assess the efficacy of bevacizumab given
through intravitreal injection at the conclusion of standard surgery for
cataract extraction on the development of diabetic retinopathy (DR) and
diabetic maculopathy postoperatively. Participants were randomized to an
institutionalized strategy of cataract surgery along with intraocular monofocal
lens implantation alone (control group; 30 eyes) or to get an intravitreal
injection of 1.25mgbevacizumab towards the finish of cataract extraction
procedure (IVB group; 27 eyes). Visual acuity with and without correction,
optical coherence tomography (OCT), and dilated fundoscopic examination were
the viablility measures checked monthly postoperatively for a total 6-months
follow-up period. There was no noteworthy contrast in central macular thickness
(CMT), BCVA, or foundational condition between the control and IVB bunches at
gauge. Progression of diabetic retinopathy was documented in 15 among 30 eyes
(50%) in the control group and 2 among 27 eyes (7.4%) in the intervention group
(P = 0.0008). 1.25 mg bevacizumab injection given through intravitreal route on
conclusion of cataract surgery was established to be efficient in keeping the
progression of DR and diabetic maculopathy in patients with DR undergoing
cataract surgery7. This study is used as reference study to
calculate sample size.
A study published in Korean journal of
ophthalmology in 2011 showed that 18% of the diabetic patients undergoing
cataract develop macular edema, with the highest incidence at the conclusion of
1 month after cataract surgery8, therefore outcome was measured at 1
month post-operatively.
Rationale of our study
was to determine effectiveness of preoperative intravitreal bevacizumab in
prophylaxis of macular edema in patients with mild to moderate diabetic
retinopathy undergoing phacoemulsification so as to improve the visual
outcomes. This study has not been previously done in
Pakistani population.
MATERIAL AND METHODS
A Randomized control trial study was
carried out to highlight that the peroperative intravitreal bevacizumab is
effective in prophylaxis of macular edema in patients with mild to moderate
NPDR, when compared to controls. Study population included patients who
reported at hospital with cataract and diabetic retinopathy. Sample size for
the study was taken by non-probability, consecutive sampling form a total of 60
participants divided into two groups, The allocation was done through simple
random sampling technique by formulating a list of randomly allocated 60
numbers in random number list generated through SPSS, 30 to group A or study
group and 30 to control group (B).The study was carried out for a period of 6
months (20th July 2016 to 19th January 2017).
For the procedure all participants were
randomly allocated in a 1:1 ratio to either have an injection of bevacizumab
(1.25 mg in 0.05 ml) through intravitreal route on the conclusion of surgery
(study group) or not (control group). A thorough ocular examination and OCT was
done 1 week prior to the surgery and then 1 month post surgery by the same
researcher in all cases. The researcher was not aware of the allocation of the
patients to the study groups. The standard ocular examination at each visit
comprised of slit lamp examination, uncorrected and best corrected visual
acuity, and quantification of the central macular thickness with OCT as an
average of three consecutive measurements. Patients underwent standard cataract
surgery (phacoemulsification and monofocal intraocular lens (IOL)
implantation). One surgeon performed all the surgeries and intravitreal
injections. Postoperatively all patients were prescribed
moxifloxacin-dexamethasone eye drops two hourly for two weeks followed by
tapering over 1 month. Every patient was followed-up and was reassessed at
completion of 1 month after baseline and occurrence of macular edema based on
central macular thickness was the outcome variable.
Results of the collected
data were entered into SPSS version 22.0. Numerical variables were described as
mean and standard deviation. While qualitative variables that included the
macular edema, the diabetic maculopathy, central macular thickness and side of
eye were reported in the form of frequency and percentages.
RESULTS
Sample was calculated from a total of 60
patients. Mean age of the study participants was reported as 61.97 ± 5.70
years. Out of the 60 participants 33 (55.0%) were females while female to male
ratio was 1.2:1. Macular edema was seen in 04 (13.33%) patients in study group
and 17 (56.67%) patients in control group. Sample selected showed that 02
(12.50%) patients reported with right eye macular and 02 (14.29%) noticed with
left eye in group A while in group B for the right eye macular edema was
reported in 08 (53.33%) of patients and 09 (60.0%) reported with left eye.
The Gender wise sample collection of
patients is described in the pie chart given below (Fig. 1).
Fig. 1: Gender wise distribution of
the patients.
The Central Macular thickness in group A
was 233.23 ± 30.16 µm and in group B was 253.21 ± 22.34 µm. Macular edema was
seen in 04 (13.33%) patients in study group and 17 (56.67%) patients in control
group (p-value = 0.0001).Distribution of patients according to side of eye is
shown in figure 2 below.
Fig. 2: Distribution of patients
according to side of eye.
Stratification of
macular edema with respect to age groups showed significant difference in
macular edema in all age groups among both groups. Similarly, statistically
significant difference was found in macular edema in female among both groups.
Stratification of macular edema with respect to side of eye has shown in Table
1 below.
Table 1: Stratification of macular
edema according to side of eye.
Side of eye |
Group A (n = 30) |
Group B (n = 30) |
P-value |
||
Macular Edema |
Macular Edema |
||||
Yes |
No |
Yes |
No |
||
Left |
02 (14.29%) |
12 (85.71%) |
09 (60.0%) |
06 (40.0%) |
0.0001 |
Right |
02 (12.50%) |
14 (87.50%) |
08 (53.33%) |
07 (46.67%) |
0.015 |
As the details of Macular edema found in
both groups are graphically shown in figure 3 below.
Fig. 3: Distribution of patients
according to macular edema in both Groups.
DISCUSSION
Diabetic maculopathy is a foremost cause of
loss of visual acuity in diabetic population9. It is well-known fact
that outcomes of cataract surgery in terms of visual acuity can be negatively
affected by DME.10It was suggested by some authors that any clear
evidence is lacking to show that phacoemulsification cataract surgery causes advancement
of DME, specifically in low-risk population; i-e, those with mild diabetic retinopathy
or with controlled retinal disease. However, it was established by Kim et al11
that 22% of the diabetic patients undergoing uncomplicated phacoemulsification
show > 30% increase in central retinal thickness as quantified by optical
coherence tomography (OCT). Numerous studies have proposed the prophylactic use
of intravitreal injection of either bevacizumab or steroids in patients with
DME that are undergoing phacoemulsification to improve the final anatomical and
physiological outcome of intervention in terms of retinal thickness and visual
acuity.12-15 I have conducted this study to determine frequency of
macular edema in patients of mild to moderate non-proliferative diabetic
retinopathy (NPDR) receiving peroperative Intravitreal bevacizumab, as compared
to controls, at completion of 1 month after phacoemulsification cataract
surgery.
Age range in this study was from 50 to 70
years with mean age of 61.97 ± 5.70 years. The participants in group A (study
group) had a mean age of 61.60 ± 5.75 years while that of participants in group
B was 62.33 ± 5.71 years. Majority of the patients 38 (63.33%) were between 61
to 70 years of age. Out of 60 patients 33 (55.0%) were females and 27 (45.0%)
were males with female to male ratio of 1.2:1. Macular edema was seen in 04
(13.33%) patients in study group and17 (56.67%) patients in control group
(p-value = 0.0001). The purpose of this study was to assess adequacy of
bevacizumab given as an intravitreal injection at the conclusion of cataract
surgery on the postoperative outcomes of surgery in terms of diabetic retinal
changes. For this purpose all the participants were randomly allocated in a 1:1
ratio to either have an intravitreal injection of bevacizumab (1.25 mg in
0.05 ml) at the completion of surgery (study group) or not (control group). Visual
acuity with and without correction, optical coherence tomography (OCT), and
dilated fundoscopic examination were the efficacy parameters checked monthly for
a 6 months post-intervention follow-up period. Noteworthy contrast was not seen
in central macular thickness (CMT), BCVA, or foundational condition between the
control and IVB groups at baseline. Progresson of diabetic retinopathy was
documented in 15 among 30 eyes (50%) in the control group and 2 among 27 eyes
(7.4%) in the intervention group (P = 0.0008).
In a study16, 42 patients with
diabetic macular edema were randomly allocated to either phacoemulsification
only or combined with intravitreal injection of bevacizumab. Macular thickness
(MT) as quantified by optical coherence tomography was ˃300μm in all patients. The eyes with PDR or those that had
received laser treatment at least 1 year before surgery were excluded.
Reassessment of CMT at first and third month after surgery, demonstrated a
substantial decrease in the intravitreal bevacizumab group in comparison to no
bevacizumab group in which it increased significantly. Likewise bevacizumab
group showed significantly higher improvement in VA as compared to the control
group; which was correlated to be due to the reduction in MT in the bevacizumab
group16.
Cheema and colleagues17investigated
as to whether intravitreal bevacizumab injection with cataract surgery prevents
postoperative diabetic macular edema (PME) in patients with stable DR with no
notable ME. Eighty patients each with visually significant lenticular opacity,
steady preproliferative DR, and no substantial ME were randomized to a sham
group (cataract surgery only), or a study group undergoing cataract surgery
with bevacizumab injection at the end of procedure. Best-corrected visual
acuities, central subfield foveal thickness, and macular volume were measured
by means of optical coherence tomography at baseline and then 1 week, 1, 3, and
6 months postoperatively. Clinically significant postoperative macular edema
(PME) was defined as >60μm increase in central subfield thickness as
compared to baseline. There was no significant difference in measured
parameters at baseline. The sham group showed significantly larger increment in
central subfield thickness at 1 week and 1 month postoperatively as compared to
baseline, larger increases in total macular volume at all follow ups, greater
development of PME at 1 month follow up, and poorer best-corrected visual
acuities outcome from baseline to 6 months post intervention. It was concluded
from the study that, intravitreal injection of bevacizumab given at the time of
surgery in patients with stable DR without significant ME, undergoing cataract
surgery might be effective in preventing the postoperative worsening of ME and
it might improve the concluding visual outcome of cataract surgery17.
In another study18, participants
were randomly allocated to a control group undergoing standard procedure of
cataract extraction followed by intraocular lens implantation alone or
intervention group to get an intravitreal injection of standard dose of
bevacizumab on the conclusion of cataract surgery. Patients were monitored
postoperatively up to a duration of 6 months specifically for development and
progression of any retinal and macular changes attributed to diabetes. In total
sixty-eight eyes were enrolled in the study. Diabetic retinal changes
progressed in 15 (45.45%) among 33 eyes
in the cataract surgery only group and 4 (11.42%) among 35 eyes in the cataract
surgery plus bevacizumab group (P = 0.002). 17 eyes (51.51%) in the control
group showed progression of maculopathy as compared to only 2 eyes (5.71%) in
the intervention group (P = 0.0001). But visual acuities did not show any
significant contrast between the 2 groups postoperatively (P = 0.772); however,
two eyes in the control group progressed to neovascular glaucoma as compared to
none in intervention group. No significant difference was seen between the mean
postoperative central macular thickness and mean macular thickness between the 2
groups (P = 0.874 and 0.942, respectively)18.
An interventional, randomized, open-label
and control study19 of two parallel groups of already diagnosed
patients with pre-proliferative diabetic retinopathy without macular edema was
done. The study included sixty eyes of sixty patients, having non-proliferative
diabetic retinopathy without macular edema and lens opacity (grade 1 to 3). One
group (n = 30) received intra-vitreal injection of Bevacizumab and the control
group (n = 30) did not received intra-vitreal injection of Bevacizumab during
standard phacoemulsification. Best-corrected visual acuity (BCVA) on the
conclusion of two months compared with the baseline visual acuity recorded
along with central macular thickness (CMT) measured on optical coherence
tomography (OCT) was the key outcome measured. The mean age of the patients was
also similar in the control (55.2 ± 9.66 years) and Bevacizumab groups (56.47 ±
9.13 years) ranging from 40 to 75 years. All of the patients in Bevacizumab
group had visual acuity of 6/6postoperatively except one eye (3.33%) had 6/12
due to CSME that was evident on OCT as increase in macular thickness. While in
control group 10 (33.33 %) eyes out of 30 had BCVA of 6/12 or less (evident on
OCT as increase in macular thickness)19.
Another study carried
out by Lanzagorta et al12 has shown improvement in the vision and
decrease in the retinal thickness in the Bevacizumab group in contrast to
control group. Mason et al20 described noticeable improvement of
visual acuity in 2 patients with persistent CME which has been effectively
treated with Bevacizumab. On the whole, it was concluded that peroperative
intravitreal bevacizumab is effective in prophylaxis of macular edema in
patients with mild to moderate NPDR, as compared to controls, at completion of
1 month after phacoemulsification cataract surgery.
CONCLUSION
The study concludes that
the peroperative intravitreal bevacizumab is effective in prophylaxis of
macular edema in patients with mild to moderate NPDR, as compared to controls,
at completion of 1 month after phacoemulsification cataract surgery. So, we
recommend that peroperative intravitreal bevacizumab should be used as a
prophylaxis of macular edema in patients with mild to moderate NPDR after
phacoemulsification cataract surgery.
Author’s Affiliation
Dr. Sidra Jabeen
F CPS, Ohthalmology
department
Holy family hospital,
Rawalpindi
Dr. Rizwan Khan
FCPS, Senior registrar,
Ophthalmology department
Holy family hospital,
Rawalpindi
Dr. Ali Raza
MCPS, FCPS, Professor,
ophthalmology department
Holy family hospital
Author’s Contribution
Dr. Sidra Jabeen
Corresponding author,
Planning of research including data collection, collection methods, setting,
collection of data, drafting.
Dr. Rizwan Khan
All surgical
interventions done, analaysis and interpretation of data.
Dr. Ali Raza
Critical revision of all
work, supervisor of research project.
REFERENCES
1.
Qazi HA.
Intravitreal administration of 1.25 mg bevacizumab at the time of cataract
surgery was safe and effective in preventing the progression of DR and diabetic
maculopathy in patients with cataract and DR. J Res Med Sci. 2012; 17: 1180–1187.
2.
Chae JB, Joe SG, Yang SJ, Lee JY, Sung KR, Kim JY, Kim JG, Yoon
YH. Effect of combined cataract
surgery and ranibizumab injection in postoperative macular edema in
nonproliferative diabetic retinopathy. Retina, 2014; 34: 149-56.
3.
Brito PN, Rosas VM, Coentrão LM, Carneiro ÂV, Rocha-Sousa A,
Brandão E, Falcão-Reis F, Falcão MA. Evaluation of visual acuity, macular status, and subfoveal choroidal
thickness changes after cataract surgery in eyes with diabetic retinopathy.
Retina, 2015; 35: 294-302.
4.
Ateeq A, Tahir MA, Cheema A, Dahri A, Tareen S. Intravitreal injection of Bevacizumab in diabetic macular edema.
Pak J Med Sci. 2014; 30: 1383-7.
5.
Salehi A, Beni AN, Razmjoo H, Beni ZN. Phacoemulcification with intravitreal bevacizumab injection in
patients with cataract and coexisting diabetic retinopathy: prospective
randomized study. J Ocul Pharmacol Ther. 2012; 28: 212-8.
6.
Bonnin S, Dupas B, Lavia C, Erginay A, Dhundass M, Couturier A,
Gaudric A, Tadayoni R. Antivascular
endothelial growth factor therapy can improve diabetic retinopathy score
without changes in retinal perfusion. Retina. 2019 Mar; 39(3): 426-434.
7.
Kwon SI, Hwang DJ, Seo JY, Park IW. Evaluation of changes of macular thickness in diabetic
retinopathy after cataract surgery. Korean J Ophthalmol. 2011; 25 (4): 238-42.
8.
Moss SE, Klein R, Klein BEK. The incidence of vision loss in a diabetic population.
Ophthalmol. 1998; 95 (10): 1340–1348.
9.
Nelson L, Martidis A.
Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol.
2003; 14 (1): 39–43.
10.
Shah AA, Chen SH.
Cataract surgery and diabetes. Curr Opin Ophthalmol. 2010; 21 (1): 4–9.
11.
Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with
diabetes using optical coherence tomography. Ophthalmol. 2007; 114 (5): 881–889.
12.
Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL,
Navea-Tejerina A. Prevention of vision
loss after cataract surgery in diabetic macular edema with intravitreal
bevacizumab: a pilot study. Retina, 2009; 29
(4): 530–535.
13.
Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on
diabetic macular edema after cataract surgery. Ophthalmol. 2009; 116 (6): 1151–1157.
14.
Akinci A, Muftuoglu O, Altınsoy A, Ozkılıc E. Phacoemulsification with intravitreal bevacizumab and
triamcinolone acetonide injection in diabetic patients with clinically
significant macular edema and cataract. Retina, 2010; 31 (4): 755–758.
15.
Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards
AR, et al. Randomized trial
evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus
prompt laser for diabetic macular edema. Ophthalmology, 2010 Jun. 117 (6): 1064-1077.e35.
16.
Ahmed M, Nawaz M, Javed EA, Sultan M. Efficacy of Intra-Vitreal Bevacizumab combined with
Phaco-Emulsification in the Prophylaxis of Macular Edema in Patients with
Non-Proliferative Diabetic Retinopathy. APMC. 2016; 10 (2): 58-62.
17.
Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab
injection in preventing progression of diabetic retinopathy: Prospective
randomized study. J Cataract Refract Surg. 2009; 35: 18–25.
18.
Klein R. The
Diabetes Control and Complications Trial. Kertes C, ed. Clinical Trials in
Ophthalmology: A Summary and Practice Guide, 1998: 49-70.
19.
Akduman L, Olk RJ.
The early treatment for diabetic retinopathy study. Kertes C, ed. Clinical
Trials in Ophthalmology: A Summary and Practice Guide, 1998: 15-36.
20.
Mason JO, Albert MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic
cystoid macular edema. Retina, 2006; 26: 356–7.